OVCAR-5Homo sapiens (Human)Cancer cell line

Also known as: OVCAR 5, NIH:OVCAR-5, OVCAR.5, OVCAR5, Ovcar5, OVCA5

🤖 AI SummaryBased on 15 publications

Quick Overview

Ovarian cancer cell line with known resistance mechanisms and genetic profiles.

Detailed Summary

OVCAR-5 is a human ovarian cancer cell line derived from an untreated patient. It is widely used in research for studying ovarian cancer biology, drug resistance mechanisms, and genetic alterations. The cell line has been characterized for its resistance to cisplatin and other chemotherapeutic agents, with studies indicating involvement of glutathione synthesis and gene amplifications in resistance. OVCAR-5 has also been used in genomic and proteomic analyses to identify molecular targets and therapeutic strategies. Its genetic profile includes mutations in key oncogenes and tumor suppressor genes, making it a valuable model for understanding cancer progression and treatment responses.

Research Applications

Drug resistance mechanismsGenomic and proteomic analysesCisplatin resistance studiesGene expression profilingMolecular target identification

Key Characteristics

Resistance to cisplatinAmplifications at 20qMutations in TP53Overexpression of glutathione-related genes
Generated on 6/17/2025

Basic Information

Database IDCVCL_1628
SpeciesHomo sapiens (Human)
Tissue SourceAscites[UBERON:UBERON_0007795]

Donor Information

Age67
Age CategoryAdult
SexFemale

Disease Information

DiseaseHigh grade ovarian serous adenocarcinoma
LineageOvary/Fallopian Tube
SubtypeHigh-Grade Serous Ovarian Cancer
OncoTree CodeHGSOC

DepMap Information

Source TypeAcademic lab
Source IDACH-001151_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleKRASp.Gly12Val (c.35G>T)HeterozygousAcquiredUnknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
10,13
D16S539
11
D18S51
12
D19S433
13,14
D21S11
31
D2S1338
17,23
D3S1358
15,16
D5S818
11,13
D7S820
10
D8S1179
13,14
FGA
23
Penta D
12
Penta E
9,16
TH01
7,9.3
TPOX
8,11
vWA
16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

Mob. DNA 7:20.1-20.11(2016).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Chemoresistant cancer cell lines are characterized by migratory, amino acid metabolism, protein catabolism and IFN1 signalling perturbations.

Hoffmann P., Klingler-Hoffmann M.

Cancers (Basel) 14:2763.1-2763.24(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Velculescu V.E., Scharpf R.B.

Cell Rep. 25:2617-2633(2018).

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Cell Rep. 18:2343-2358(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Anderson M.E.

Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

J. Natl. Cancer Inst. 83:757-766(1991).

Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.

Ozols R.F., Fojo A., Hamilton T.C.

Int. J. Cancer 45:416-422(1990).

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

Characterization of immunotoxins active against ovarian cancer cell lines.

Frankel A.E., Willingham M.C., Pastan I.

J. Clin. Invest. 76:1261-1267(1985).

Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.

Hamilton T.C., Young R.C., Ozols R.F.

Semin. Oncol. 11:285-298(1984).

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

van Zijl P.L.

Eur. J. Cancer 31A:230-237(1995).

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.

Cancer Res. 57:850-856(1997).

Systematic variation in gene expression patterns in human cancer cell lines.

Botstein D., Brown P.O.

Nat. Genet. 24:227-235(2000).

Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.

Takayama M., Sato A., Inazawa J.

Jpn. J. Cancer Res. 93:1114-1122(2002).

Gene expression patterns in ovarian carcinomas.";

Sikic B.I.

Mol. Biol. Cell 14:4376-4386(2003).

HLA class I and II genotype of the NCI-60 cell lines.";

Morse H.C. 3rd, Stroncek D., Marincola F.M.

J. Transl. Med. 3:11.1-11.8(2005).

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mol. Cancer Ther. 5:2606-2612(2006).

DNA fingerprinting of the NCI-60 cell line panel.";

Chanock S.J., Weinstein J.N.

Mol. Cancer Ther. 8:713-724(2009).

S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.

Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.

Am. J. Clin. Pathol. 132:846-856(2009).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Oncol. Rep. 23:1021-1026(2010).

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Ambudkar S.V., Gottesman M.M.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).

Genomic complexity and AKT dependence in serous ovarian cancer.";

Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.

Cancer Discov. 2:56-67(2012).

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Kong D.-X., Yamori T.

Bioorg. Med. Chem. 20:1947-1951(2012).

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

PLoS ONE 7:E31628-E31628(2012).

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

Yoon C.N., Chang Y.-T.

PLoS ONE 7:E32096-E32096(2012).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Science 336:1040-1044(2012).

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Mills G.B., Hennessy B.T.

Mol. Oncol. 7:567-579(2013).

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

Cancer Res. 73:4372-4382(2013).

Global proteome analysis of the NCI-60 cell line panel.";

Wilhelm M., Kuster B.

Cell Rep. 4:609-620(2013).

Type-specific cell line models for type-specific ovarian cancer research.

Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

PLoS ONE 8:E72162-E72162(2013).

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Hirshfield K.M., Oltvai Z.N., Vazquez A.

Cancer Metab. 1:20.1-20.13(2013).

In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.

Kislinger T.

Biochem. Biophys. Res. Commun. 445:694-701(2014).

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

PLoS ONE 9:E92047-E92047(2014).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Noonan A.M., Annunziata C.M.

Gynecol. Oncol. 142:332-340(2016).

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.

Capes-Davis A., Harkin D.P., Gourley C., Kennedy R.D.

Nucleic Acids Res. 44:e137.1-e137.10(2016).

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Vandesompele J.

Sci. Data 3:160052-160052(2016).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.

Nat. Commun. 7:12645.1-12645.14(2016).